Abstract Non-cell autonomous involvement of glial cells in the pathogenesis of polyglutamine diseases is gaining recognition in the ataxia field. We previously demonstrated that Purkinje cells (PCs) in polyglutamine disease spinocerebellar ataxia-1 (SCA1) contain cytoplasmic vacuoles rich in Bergmann glial protein S100B. The vacuolar formation in SCA1 PCs is accompanied with an abnormal morphology of dendritic spines. In addition, S100B messenger RNA (mRNA) expression levels are significantly high in the cerebella of asymptomatic SCA1 transgenic (Tg) mice and increase further with age when compared with the agematched wild-type animals. This higher S100B mRNA expression positively correlates with an increase in the number of vacuoles. To further characterize the function of S100B in SCA1 pathology, we explored the effects of S100B protein on GFP-ataxin-1 (ATXN1) with expanded polyglutamines [82Q] in HEK stable cell line. Externally added S100B protein to these cells induced S100B-positive vacuoles similar to those seen in SCA1 PCs in vivo. Further, we found that both externally added and internally expressed S100B significantly reduced GFP-ATXN1[82Q] inclusion body formation. In contrast, the addition of S100B inhibitory peptide TRTK12 reversed S100B-mediated effects. Interestingly, in SCA1 Tg mice, PCs containing S100B vacuoles also showed the lack of nuclear inclusions, whereas PCs without vacuoles contained nuclear inclusions. Additionally, TRTK12 treatment reduced abnormal dendritic growth and morphology of PCs in cerebellar slice cultures prepared from SCA1 Tg mice. Moreover, intranasal administration of TRTK12 to SCA1 Tg mice reduced cerebellar S100B levels in the particulate fractions, and these mice displayed a significant improvement in their performance deficit on the Rotarod test. Taken together, our results suggest that glial S100B may augment degenerative changes in SCA1 PCs by modulating mutant ataxin-1 toxicity/ solubility through an unknown signaling pathway.
Introduction
Spinocerebellar ataxia type1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by progressive ataxia due to the loss of cerebellar Purkinje cells (PCs) and neurons in the brainstem [1] [2] [3] . A polyglutamine expansion in the disease causing protein ataxin-1 is known to be the major player in neuronal degeneration; however, the exact function of mutant ataxin-1 is still debated [2, 4, 5] . In B05 SCA1 transgenic (Tg) mice, the expression of mutant ataxin-1 transgene PS-82 produces progressive ataxia and PC pathologic changes mirroring those seen in SCA1 patients [6] . In these mice, the most prevalent features of SCA1 disease are the development of cytoplasmic vacuoles and the presence of nuclear inclusions in PCs. However, vacuole development precedes both nuclear inclusion formation and behavioral abnormalities [7] [8] [9] . Recently, we reported that Bergmann glia (BG) protein S100B localizes to SCA1 PC vacuoles in both SCA1 Tg mice and SCA1 patients, and vacuolar formation is associated with abnormal PC morphology [8, 9] . The mechanistic link between mutant ataxin-1 expression and S100B vacuole development is not well established yet and needs further investigation.
The astrocytic S100B protein belongs to the EF-hand family of calcium-binding proteins [10, 11] . S100B is abundantly expressed in the nervous system and can function as a neurotrophic signaling molecule or as a neurotoxic agent [11] [12] [13] [14] . Neurotrophic expression of S100B promotes neuronal survival and development [15] [16] [17] . Increased levels of S100B have also been reported in brain injury, Alzheimer's disease, and Down syndrome [14, 18, 19] . S100B has been shown to interact with multiple protein targets including p53, nuclear Dbf2-related kinases, receptor for advanced glycation end products, protein kinase C, neuromodulin, and myoinositol-monophosphatase-1 [9, [20] [21] [22] .
Cell bodies of BG are located in the PC layer of the cerebellar cortex. BG form rosettes around PCs and ensheathe their dendrites and synapses to maintain and regulate PC structure and function, respectively [23, 24] . BG climbing fibers are said to guide granule cell migration during cerebellum development and to provide a scaffold for growing PC dendritic arborizations [23] . Damaged BG have been shown to cause degeneration of PC dendrites, granule cell death, and impaired motor coordination [25] . We also indicated earlier [9] that BG may mediate SCA1 pathology via S100B vacuoles, which localize to the PC cytoplasm and demonstrated that PCs with vacuoles show severe atrophy of dendrites and spines as compared to cells without vacuoles [9] . Our data are supported by a recent report on SCA1 knockin mice suggesting that functional deficiency of BG may contribute to PC pathology in SCA1 [26] . Similar alterations in PCs were seen when ataxin-7 was expressed in BG in SCA-7 mouse model [27] . We believe that BG-dependent pathways initiating PC death may be common to multiple neurodegenerative diseases. In this study, we further characterize the role of BG in SCA1 pathogenesis and show that S100B protein may directly influence ataxin-1 toxicity and/or solubility.
Materials and Methods

Materials
Paraformaldehyde (PFA), biochemicals, and culture media were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was purchased from HyClone (Logan, UT, USA). Fugene 6 transfection reagent and green fluorescent protein (GFP) antibody were purchased from Roche (Indianapolis, IN, USA). S100B antibody was purchased from Abcam (Cambridge, MA, USA) and S100B protein was purchased from Sigma-Aldrich. Ubiquitin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TRTK12 and 5FAM-labeled TRTK12 peptides were purchased from AnaSpec (San Jose, CA, USA). [31] . HEK cells were transfected using Fugene 6 transfection reagent (Roche) according to the manufacturer's guidelines to express GFPataxin-1[82Q] followed by selection with G418 antibiotic (G418 sulfate 600 μg/ml, Sigma) to produce GFP-ataxin-1 [82Q] stable cell lines. HeLa cells were transfected using Fugene 6 transfection reagent to express S100B followed by selection with G418 antibiotic to produce S100B stable cell lines.
Cell
Immunofluorescence, Co-immunoprecipitation, and Western Blotting GFP-ataxin-1[82Q] HEK cells were transferred to two-well chamber slides (Fisher) and treated with 500 nM S100B for 24 h. HeLa cells placed on two-well slides were treated with Alexa-594-S100B. Bovine S100B protein (Sigma) was labeled with Alexa-594 dye using Alexa-Fluor-594 protein labeling kit (Invitrogen) according to the manufacturer's guidelines. Slides were fixed with 4% PFA and probed with appropriate GFP or S100B antibodies and fluorescent secondary antibodies Alexa 488 and Alexa 546 (Invitrogen). Cells were observed on an Olympus BX60 epi-fluorescence microscope. GFP-ataxin-1[82Q] inclusions in the transfected cells were scored according to the method described by Parfitt and co-workers [32] as soluble (diffuse localization within the nucleus), as small punctate foci, or as larger inclusions [32] . For each group of cell culture experiment, around 100 cells were counted per treatment group and each experiment was repeated for a total of three times. Averages and standard errors were taken and statistics were calculated using Student's t test. For Western blotting, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, and 1% NP-40, Sigma), followed by brief sonication as previously described [33] . Co-immunoprecipitation of S100B and GFP-ataxin-1 was performed using Seize X Protein A Plus IP kit (Pierce, Rockford, IL, USA) as previously described [9] . Bead bound proteins were mixed with SDS-PAGE sample buffer, followed by boiling for 5 min. Samples were resolved by SDS-PAGE as previously described [9] .
SCA1 Transgenic Mice
The SCA1 Tg mice were generated and kindly provided by Drs. Harry Orr and Huda Zoghbi [6] . Colonies of SCA1 Tg mice are maintained in our animal facility. The heterozygous PS-82 BO5 line of mice were identified using a transgene specific polymerase chain reaction assay and were backcrossed to the parental FVB/N strain (N=10) to establish congenic line with homogeneous background strain [9] . The line B05 expresses 30 copies of the transgene PS-82. B05 Tg mice develop progressive loss of PCs and cerebellar function. Heterozygous B05 mice become visibly ataxic at 12 weeks of age and homozygous B05 mice show ataxia at 6 weeks of age.
Green Fluorescent Protein Transgenic Mice
Homozygous GFP mice and wild-type (same background) were obtained from Jackson Labs, Bar Harbor, Maine. We have a colony of GFP transgenic mice in our animal facility [9] . The transgene expression of enhanced GFP gene is under the control of pcp2/L7 promoter similar to ataxin-1 expression in SCA1 mice and GFP is expressed only in Purkinje cells, where it fills dendrites, soma, axons, and nuclei. GFP is detected in PCs as early as E17 and increases during development. There is no PC pathology or behavioral abnormalities in these mice.
Generation of Experimental Animals
SCA1/GFP Mice Female mice (FVB/N) homozygous for SCA1 (SCA1/SCA1) were mated with male (FVB/N) homozygous (GFP/GFP) GFP mice to generate double mutants heterozygous for both SCA1 and GFP (SCA1/+:GFP/+).
Wild-Type/GFP Homozygous GFP (GFP/GFP) males (FVB/N) were mated with wild-type (+/+) females (FVB/N) to generate heterozygous (GFP/+) mice wild-type for SCA1.
The manipulation and maintenance of animals were approved by the Institutes of Animal Care and Use Fig. 1 a Shown is an image of the end point PCR results after 30 cycles of amplification for both S100B and β-actin cerebellar cDNA from 2-and 4-week-old WT and SCA1 Tg mice. Band intensities were taken using ImageJ software and used to estimate the mRNA levels of S100B compared to β-actin for each group. b Graph displays the mean ± SE of the relative mRNA levels of S100B compared to β-actin. c Graph displays the mean ± SE of the relative gene expression of S100B among the different groups using real-time PCR technique, where β-actin was used as the housekeeping gene. Statistical significance was calculated using Student's t test. S100B mRNA levels are significantly up-regulated in the cerebellum of SCA1 mice compared to WT mice of the same background, *P<0.01
Committee. This committee enforces the regulations for using animals in scientific research at the University of Mississippi Medical Center (UMMC), Jackson, MS, USA.
Purkinje Cell Cultures
Cerebellar slice cultures were prepared from 7-11-day-old SCA1 Tg mouse pups. The whole cerebella were obtained after sacrifice and meninges were carefully removed using a dissection microscope. Tissue was rinsed and placed in Petri dishes containing 5% glucose and cold Gey's balanced salt solution (Gey solution, Sigma). Cerebellar tissues were cut into 250 μm slice sections using a McIlwain tissue chopper. Cerebellar slices were resuspended in cold Gey solution containing 5% glucose, then grown on Millicell membrane inserts (Fisher) using six-well culture plate containing 1 ml plating media (for 100 ml media: 5 ml 10× basal medium with Earle's salt, 2.5 ml 10× HBSS, 25 ml horse serum (Invitrogen), 1 ml 100× Pen-Strep-glutamine, 4.5 ml 10% Dglucose, 0.5 ml 7.5% sodium bicarbonate, and 61.5 ml sterile water, Sigma). Tissue-cultured plates were incubated overnight at 35.5°C with 5% CO 2 and 100% humidity. The next day, cells were flushed and treated with various concentrations of TRTK12 in plating media. Cultures were fixed in 4% PFA, placed on plus slides (Fisher), and then immunostained using GFP antibody followed by fluorescent secondary antibody Alexa 488. Tissues were observed on an Olympus BX60 epi-fluorescence microscope.
End Point and Real-Time PCR RNA from whole cerebellar homogenates was isolated from 2-and 4-week-old FVB WT and SCA1 Tg heterozygous (Het) mice using the Absolutely RNA mini prep kit (Stratagene). The RNA quality was measured by Lab Chip RNA 6000 Nano Assay (Agilent Technologies, Santa Clara, CA, USA) using the UMMC core facility MFGN INBRE Program of the National Center for Research Resources (NIH Grant Number RR 016476-09A1). Next, 2 μg of RNA was used to produce complementary DNA (cDNA) using the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA). S100B and β-actin primers (IDT, San Jose, CA, USA) were used to amplify the cDNA for 30 cycles using the Taq PCR kit (Qiagen, Valencia, CA, USA) and a PCR machine. S100B forward primer: CTGGAGAAGGCCATGGTTGC, S100B reverse primer: CTCCAGGAAGTGAGAGAGCT, product size, 110 bp; β-actin forward primer: GTGGGCCGCTCTAGG CACCAA, β-actin reverse primer: CTCTTTGATGTCAC GCACGATTTC, product size, 540 bp. Amplified DNA was run on a 2% agarose gel containing 0.005% ethidium bromide. The DNA gel was visualized using a UV Bio-Rad Imaging Station (Bio-Rad Laboratories, Hercules, CA, USA). Band intensity values were taken using ImageJ software. Graph displays the mean ± SE of the relative messenger RNA (mRNA) levels of S100B compared to β-actin. Statistical analysis was calculated using Student's t test. cDNA was then used for real-time PCR using Fast EvaGreen qPCR Master Mix (Biotium, Hayward, CA, USA) and the reactions were subjected to a 10-min incubation at 95°C, followed by 40 amplification cycles (95°C for 30 s, 50°C for 30 s, 72°C for 1 min), and a dissociation curve analysis step. The reactions were conducted using a MX3000P or a MX3005P real-time PCR system (Stratagene, Cedar Creek, TX, USA). Amplification rates, Ct values, and dissociation curve analyses of products were determined using MxPro (version 4.01) software. Relative expression was determined using the 2(−ΔΔCt) method [34] . Student's t test was used to determine Fig. 2 a HeLa cells were transferred to two-well slides and treated with 2.0 μM 594-S100B for 6 h followed by fixation and DAPI staining. Fluorescent microscopy displays DAPI nuclear staining in blue and 594-S100B in red. Scale bars 10 μm. b HeLa cells were transferred to six-well plates and treated with 2.0 μM unlabeled S100B protein for 6 h. Cells were washed with PBS and lysed in the plates using nuclear/cytosol fractionation Kit (BioVision, Mountain View, CA, USA) according to the manufacturer's protocol. Isolated nuclear and cytosolic fractions were subjected to Western blotting followed by detection using the S100B antibody. S100B localized both to the nucleus and cytoplasm of HeLa cells statistical significance and P value of less than 0.05 was considered as statistically significant.
Tissue Processing Spinocerebellar ataxia-1 Tg heterozygous or homozygous mice at different postnatal days were anesthetized and perfused with 4% buffered PFA according to the method described by Neuroscience Associates, Knoxville, TN, USA. The brains were removed and immersed in the perfusion fixative then transferred to phosphate-buffered saline and processed for vibratome sectioning or paraffin embedding as previously described [9] . Sections were cut from the midline sagittal plane of the cerebella. Sections were double immunostained for ubiquitin and S100B using the immunohistochemical protocol as previously described [9] .
Intranasal Administration of TRTK12 Two-week-old GFP: SCA1 animals were randomly divided into two treatment groups-the TRTK12 group (10 μg/animal) (n=9) and a vehicle (normal saline)-treated disease control group (n=6). TRTK12 was administered via intranasal (IN) route [35] . Anesthetized mice were placed on their backs, and 10-μl solution (containing TRTK12, 1.0 μg/μl, or normal saline as vehicle) per mouse was administered through the nose. The subsequent doses were given at 48-h intervals for 3 weeks. After completion of the treatment, animals were subjected to accelerating rotarod test [35] followed by immunohistochemical and Western blot analysis according to the methods described previously [9] . The Western blot membranes were probed overnight with the appropriate concentration antibodies followed by alkaline phosphataselabeled secondary antibody and luminescent substrate. The blots were visualized on hyperfilm-ECL (Amersham Biosciences, Buckinghamshire, UK).
Accelerating Rotating Rod Test
The rotating rod apparatus (Harvard Apparatus, Holliston, MA, USA) was used to measure the ability of mice to improve motor skill performance with training. Starting 24 h after the completion of the last dose, mice comprising the saline and TRTK12 groups were put on the rod (3 cm in diameter) for trials four times per day for four consecutive days. Each trial lasts a maximum of 6-10 min, during which time the rotating rod undergoes a linear acceleration from 4 to 40 rpm over the first 5 min of the trial and then remains at maximum speed for the remaining 5 min. Animals rested a minimum of 10 min between trials to avoid fatigue and exhaustion. The mice were scored for their latency to fall (height=20 cm) (in seconds) for each trial. The results were analyzed by a two-way repeated measures ANOVA that factors genotype, day, and trial using GraphPad Prism software, version 4.0 (GraphPad Software, San Diego, CA, USA). A value of P<0.05 was accepted as statistically significant.
Results
PC S100B Vacuole Formation Correlates with Increasing
Expression of S100B in the SCA1 Cerebellum
The appearance of S100B vacuoles in PCs is the earliest morphological change that precedes behavioral abnormalities in SCA1 Tg mice. Similar vacuoles are seen in the surviving PCs of SCA1 patients [8, 9] . In SCA1 Tg mice, S100B vacuoles appear between 2 to 3 weeks after birth, which corresponds to a critical period of cerebellar development when BG stop proliferating and begin interacting with PCs [23, 24] . To further determine if vacuolar formation is associated with higher expression levels of S100B, we performed expression profiling of S100B mRNA in the cerebellar tissue of 2-and 4-week-old SCA1 Tg and age-matched wild-type (WT) mice by using end point PCR and real-time PCR techniques. In SCA1 Tg mice, both at 2 and 4 weeks, S100B expression increased significantly as compared to the WT animals (Fig. 1a, b) . The data shown in Fig. 1b were calculated using the expression of β-actin as a housekeeping gene where relative mRNA levels of S100B were compared to β-actin levels (Fig. 1a) . These observations were re-confirmed by real-time PCR (Fig. 1c) . These data suggest that PC vacuolar formation may be mediated by the increased expression levels of S100B in BG with advancing age.
S100B Localizes to Cytoplasm and Nucleus in Cultured
Cell Lines S100B is known to have both intracellular and extracellular functions. S100B excreted from astrocytes can target cells externally via binding to the specific receptors or may be internalized and act as an intracellular regulator [36] . To further establish that S100B can be internalized in cell culture models, we labeled S100B with Alexa-594 fluorescent dye (594-S100B) and treated HeLa cells with varying HEK stable cells were transferred to two-well slides and treated with b 500 nM S100B protein for 24 h followed by fixation and immunostaining and c treated with 500 nM 594-S100B for 24 h followed by fixation. Fluorescent staining shows DAPI nuclear stain in blue, GFP-ATXN1 [82Q] in green, and S100B or 594-S100B in red. In less than 10% of cells, S100B treatments resulted in vacuolar formations, indicated by arrows, similar to those seen in SCA1 PCs [6, 9] . Scale bars 10 μm. d HEK GFP-ATXN1[82Q] stable line was treated for 24 h with 2% FBS as control, with 250 nM S100B, 250 nM S100B + 1 μM TRTK12, or with 1 μM TRTK12 alone. Cells expressing ataxin-1 inclusions were scored as small punctate foci or large inclusions as described previously [33] . Data are presented as mean ± SE. Statistical significance was calculated using Student's t test. *P<0.005, S100B vs control or S100B vs S100B + TRTK12; *P>0.5, control vs S100B + TRTK12 or control vs TRTK12 concentrations of labeled S100B. In agreement with our previous report where we demonstrated that fluorescentlabeled S100B localized to the cytoplasm and nucleus of PCs in cerebellar tissue cultures [9] , 594-S100B treated HeLa cells showed S100B fluorescence both in the cytoplasm and nucleus (Fig. 2a) . In addition, the Western blot analysis of various fractions prepared by treating HeLa cells with 2.0 μM of unlabeled S100B protein showed that S100B localized to both cytosolic and nuclear HeLa cell fractions (Fig. 2b) . Furthermore, we created a stable S100B expressing HeLa cell line and observed a similar localization of S100B to the cytoplasm and the nucleus in S100B expressing cells (Fig. 3a) . These results strengthen our argument that S100B released by BG is internalized by adjacent neurons in the cerebellum.
S100B Increases Mutant Ataxin-1 Solubility
Ataxin-1 is a self-associating nuclear protein that aggregates to form nuclear inclusion bodies [37] . To explore the possibility that S100B may affect mutant ataxin-1 function, we transfected WT HeLa cells and S100B expressing HeLa cell line with GFP-ATXN1[82Q] and monitored changes in mutant ataxin-1 inclusion formation (Fig. 3a, b) . Cells expressing GFP-ATXN1[82Q] have been reported to display three phenotypes: soluble nuclear staining, small punctate foci, and large nuclear inclusions [32, 33] . We saw an inverse relation between S100B expression and mutant ataxin-1 inclusion formation. Cells expressing both S100B and GFP-ATXN1[82Q] showed a significant increase in soluble ataxin-1 and a significant reduction in the number of large inclusions as compared to cells expressing GFP-ATXN1 [82Q] alone (Fig. 3a, b) . We investigated the possibility that S100B and the mutant ataxin-1 protein may be interacting directly by co-immunoprecipitation using lysates of HeLa cells expressing both GFP-ATXN1 and S100B protein. We did not find any direct interaction between these two proteins (data not shown). It could be argued that our results where co-expression of GFP-ATXN1[82Q] and the S100B protein reduces inclusion formation may be due to a competition for protein expression between S100B and GFP-ATXN1. To rule out the possibility of variable protein expression, we (Fig. 4a) and treated these cells externally with the S100B protein and labeled 594-S100B. 594-S100B-treated GFP-ATXN1[82Q] HEK showed a similar S100B localization pattern both to the nucleus and cytoplasm (data not shown) as shown in HeLa cells treated with 594-S100B (Fig. 2a) . However, in some GFP-ATXN1[82Q] HEK cells, immunostaining of S100B-treated (Fig. 4b) as well as 594-S100B-treated cells (Fig. 4c) displayed S100B-positive vacuole formation similar to that seen in SCA1 PCs. Interestingly, the cells with S100B vacuoles lacked nuclear ataxin-1 inclusion bodies (Fig. 4b, c) . Furthermore, we found that the GFP-ATXN1[82Q] expressing HEK cells showed a significant reduction in the number of large inclusions when treated with 250 nM S100B (Fig. 4d) . S100B-treated GFP-ATXN1 [82Q] HEK cells showed significantly more small punctate ataxin-1 foci as compared to the untreated controls. S100B treatment significantly reduced the number of cells with large inclusions by half compared to untreated cells. Furthermore, reduction in the large inclusions was significantly impeded by pre-incubation with the S100B inhibitor, TRTK12 (Fig. 4d) . TRTK12 peptide has a high binding affinity for S100B with the capabilities to block S100B interaction with its target proteins [38] [39] [40] . The fact that TRTK12 treatment hindered the S100B effect on inclusion size demonstrates that S100B may play a role in mutant ataxin-1 inclusion formation. Take together, our data suggest that S100B may reduce mutant ataxin-1 inclusion formation and may increase ataxin-1 solubility through an unknown mechanism.
SCA1 PCs with S100B Vacuoles Do Not Contain Ataxin-1 Nuclear Inclusion Bodies
To further explore if the reduction in mutant ataxin-1 inclusions is related with S100B vacuoles in vivo, we looked at PCs containing S100B vacuoles and nuclear Fig. 6 GFP immunofluorescence of organotypic cerebellar slice cultures prepared from 7-day-old GFP/SCA1 Tg and GFP/WT mice. a 250-μm-thick slices were grown on Millicell membrane inserts using six-well culture plates. One day in vitro (DIV) old slices were grown in the culture media with or without 10 μM TRTK12 for 21 DIV followed by fixation and immunocytochemistry. The digitized images show abnormally developed dendritic processes in SCA1 slices without TRTK12 as compared with SCA1 slices treated with TRTK12. b TRTK12 showed no effect in WT PCs grown in the media containing TRTK12 compare to WT controls. c The digitized images were used to compare PC dendritic lengths after TRTK12 treatment.
Dendritic length was measured (n=40) using ImageJ software. Data are displayed as mean ± SE. *P<0.01. d The digitized images were used to compare total PC dendritic branch area after TRTK12 treatment. Dendritic areas were measured (n=16) using ImageJ software, where the total dendritic branch area was taken by converting the image to black pixels and analyzing the total pixel area for each PC. The data were then normalized to the controls, where control values are equal to 100. Data are displayed as mean ± SE. Statistical significance was calculated using Student's t test. *P< 0.01, SCA1 control vs SCA1 TRTK12 inclusions in 10-week-old SCA1 Tg homozygous mice. This age group was chosen because at this age a significant number of PCs contain ataxin-1 nuclear inclusion bodies. The cerebellar sections were cut in a sagittal plain, and for comparison, we counted PCs in lobes I-III. Interestingly, PCs with S100B vacuoles did not show intranuclear inclusions (Fig. 5a) . In 100% of the cells counted, over 50% of PCs had nuclear inclusions and around 20% cells contained S100B vacuoles (Fig. 5b) . However, only 3% of PCs had both vacuoles and inclusions (Fig. 5b) . These results suggest that SCA1 PCs with S100B vacuoles may contain a more soluble form of ataxin-1. Also, we examined 4-and 6-week-old SCA1 Tg heterozygous animals and found that vacuole formation was significantly higher at 6 weeks of age (Fig. 5c) , although PC number between 4 and 6 weeks of age was not significantly different in the areas used for PC counting (not shown). Intriguingly, the significant difference in S100B vacuole number in 6-week-old animals coincides with age of onset of behavioral deficits in SCA1 Tg mice [6, 9] . Furthermore, ataxin-1 nuclear inclusion bodies are rarely seen at this age [6, 9] .
TRTK12 Peptide Treatment Improves SCA1 Morphology in Cerebellar Slice Cultures
Previously, we demonstrated that S100B vacuolar formation is associated with alterations in the morphology of dendritic spines of SCA1 PCs [9] . The neurotoxic properties of S100B and its role in neurodegenerative diseases are well documented. Inhibition of S100B proteins may have beneficial effects in SCA1. We investigated the effects of S100B inhibitory peptide TRTK12 on the growth of SCA1 PCs and WT PCs expressing the GFP protein in cerebellar slice cultures. Cultured SCA1 PCs showed morphological changes represented by decreased dendritic arborations as well as dendritic atrophy (Fig. 6a) , consistent with those seen in vivo [9] . We observed that SCA1 cerebellar cultures grown for different days in vitro (DIV) in the presence of 10 μM TRTK12 displayed increased PC dendritic growth compared to untreated cultures (Fig. 6a) . In addition, TRTK12-treated SCA1 PC slices showed a significant increase in dendritic length and induction in dendritic branching (Fig. 6c, d ). In contrast, TRTK12 treatment had a lesser impact on the growth of GFP WT PC slices (Fig. 6b-d) .
To further explore the therapeutic properties of the TRTK12 peptide, we administered TRTK12 via the IN route to SCA1 Tg mice as previously described [35] . IN administration offers a non-invasive alternative to traditional administration routes (e.g., IV, SC, or IM) for the systemic delivery of therapeutics (such as proteins) that are known to possess poor oral bioavailability [41] . Fluorescent-labeled TRTK12 peptide when given IN accumulated in the cerebellum within 2 h post-administration in 4-week-old SCA1 Tg mice (Fig. 7a) , distinctly labeling PCs (Fig. 7b) . Neurons in other brain regions also showed differential distribution of TRTK12 (data not shown). Next, 2-week-old GFP/SCA1 Tg animals were treated IN with a 10-μl solution containing unlabeled TRTK12 or with saline (vehicle) as a control for a 3-week period. Interestingly, Western blot analysis of S100B in cerebellar particulate fractions prepared from saline-and TRTK12-treated animals showed a significant decrease (P<0.01) in S100B levels in the particulate fractions of the TRTK12-treated group (Fig. 8a, b) . These data indicate that there may be a lesser S100B translocation to the membranes (to form vacuoles) in the TRTK12-treated group as compared to the saline-treated animals. TRTK12 treatment showed no adverse effects on SCA1 animals as evident from the gain in weight presented in Fig. 8c . Most intriguing observation was that the TRTK12-treated animals, significantly improved their performance on the rotarod as compared to the saline-treated group (Fig. 8d ). An accelerating rotating rod apparatus measures the motor performance ability of the mice during repeated exposure to the task. In summary, our data suggest that glial S100B may influence SCA1 pathology both at the morphologic and molecular levels.
Discussion
Non-cell autonomous effect of glial cells has been implicated in several neurodegenerative disorders; however, molecular mechanistic pathways involved in the toxicity are currently not identified. In the mouse cerebellum, BG proliferate until the second postnatal week [23, [42] [43] [44] and this time point overlaps well with the S100B vacuole formation in PCs in a SCA1 Tg mouse [9] . Normal number and function of BG is vital for PC survival [25] . S100B released from glial cells in low concentrations promotes neuronal survival and development; in contrast, higher levels of S100B cause neurotoxicity [13] [14] [15] [16] [17] [18] [19] . We also found by expression profiling analysis that the expression of S100B mRNA is increased in the cerebellum in SCA1 mice with increasing postnatal age (Fig. 1) . In addition, external addition of S100B or over-expression of S100B in transfected cells carrying mutant ataxin-1 causes reduction in the number of ataxin-1 nuclear inclusions (Figs. 3 and 4) . Further, using cerebellar slice cultures and in vivo treatment of SCA1 Tg mice with S100B inhibitory peptide TRTK12, we showed that inhibition of S100B function caused reversal of S100B-mediated effects and improved behavior deficits. Furthermore, our preliminary studies on genomewide cerebellar gene expression profiling have shown that the expression of BG and PC specific genes involved in cell adhesion, signaling, and guidance are significantly dysregulated in 2-week-old SCA1 mice (unpublished observations). Therefore, we speculate that the sustained expression of mutant ataxin-1 as a transcriptional repressor may generate a stress signal, which causes BG to react and release high levels of S100B protein. S100B has been used as a marker for brain injury [45] . Elevated levels of S100B in response to neuronal dysfunction have been reported in many neurodegenerative disorders including Down syndrome and Alzheimer disease [14, 18] . Further, Gerlach and co-workers [46] using astrocyte cultures showed that astrocytes actively secrete S100B during metabolic stress. In sum, the above observations indicate that BG may be the up-stream site of ataxin-1 mediated pathology in SCA1. Fig. 8 a Western blots showing S100B and beta III tubulin in the cerebellar particulate fractions prepared from SCA1 Tg saline-(n=3) and TRTK12-treated (n=3) animals. b The S100B-tubulin band intensity ratios were calculated using ImageJ software. A significant decrease (*P<0.01) in S100B levels (in the particulate fractions) was observed after TRTK12 treatment. Student's t test for independent samples was used for calculating statistically significant differences (GraphPad Prism software). The data are presented as the mean ± SE. c Graph shows the changes in the body weight during IN normal saline and TRTK12 treatments to SCA1 Tg animals. No significant differences in the body weight were observed. d Rotarod test of SCA1 Tg mice treated IN with saline and TRTK12. A minimum of six animals/group were used. Mice were subjected to four trials/day for four consecutive days. The data were normalized to 100 for the performance on day 1. The results are presented as the mean ± SE. Two-way ANOVA with Bonferroni posttest was used for calculating statistically significant differences (GraphPad Prism software). *P <0.01, saline-treated vs TRTK12-treated Ataxin-1 is a self-associating protein, where removal of the self-associating domain prevents mutant ataxin-1 inclusion formation [37] . SCA1 Tg mice expressing mutant ataxin-1 lacking the self-association domain develop progressive ataxia similar to B05 SCA1 Tg mice that contain the intact self-association domain [37] . The soluble form of the mutant ataxin-1 protein has been suggested as the neurotoxic form of the misfolded protein [37, 47] . Therefore, processes that increase mutant ataxin-1 solubility could be considered as modulators of ataxin-1 neurotoxicity. Watase and co-workers [47] targeted 154 CAG repeats into the endogenous mouse locus. SCA1(154Q/2Q) mice developed a progressive neurological disorder accompanied by PC loss and age-related hippocampal synaptic dysfunction. Mutant ataxin-1 solubility varied with brain region, being most soluble in the neurons most vulnerable to degeneration especially PCs [47] . Furthermore, we and others have shown earlier in B05 SCA1 Tg mice that several essential PC proteins are down-regulated prior to the appearance of intranuclear inclusions [48] [49] [50] . Interestingly, ataxin-1 has been shown to interact with a whole host of transcription factors; furthermore, ataxin-1 has been shown to occupy the dopamine 2 receptor (D2R) promoter to co-regulate D2R gene expression [51] . It is enticing to think that BG may play some part in regulating mutant ataxin-1 solubility enhancing PC degeneration. This argument is supported by the fact that PCs containing S100B vacuoles lack ataxin-1 nuclear inclusions (Fig. 5) , and these cells are usually at a higher degenerative state as indicated by dendritic and spine abnormalities [9] . S100B is constitutively secreted by astrocytes and its secretion can be regulated by a number of factors [36] . Accumulating evidence suggests that intracellular regulatory activities of S100B differ substantially from its extracellular effects [52] [53] [54] . We believe that glial S100B internalized in PCs may be affecting physiologic processes vital for PC survival as indicated by our previous study where we found that S100B in PC vacuoles is co-localized with IMPase 1, an important enzyme regulating inositol 1, 4, 5 trisphosphate signaling in PCs [9] . The S100B protein also regulates nuclear Dbf2-related 2 (NDR2) protein kinase by stimulating its autophosphorylation [55] . NDR2 belongs to the subfamily of serine/threonine kinases that control cell division and morphogenesis in various cell types, including neurons [55, 56] . NDR2 is highly expressed in cerebellar PCs and show a predominant cytoplasmic localization [56] . Stork et al. [56] studied the function of NDR2 on neurite growth and reported that NDR2 negatively regulates substrate adhesion in differentiated PC12 cells, possibly by reducing the stability of actin-dependent contact sites. We speculate that the sustained presence of S100B vacuoles in differentiating PCs in SCA1 may act as a constant source of S100B to activate PC NDR2 kinase, which in an activated state destabilizes BG-PC contact sites and neurite growth resulting in PC degeneration. A stronger argument suggesting the S100B involvement in SCA1 neurodegeneration comes from the beneficial effects of TRTK12 both on SCA1 slice cultured PCs and IN-treated SCA1 Tg mice (Figs. 6, 7, and 8) . The fact that S100B inhibition improves SCA1 phenotype suggests that BG S100B may play a key role in the SCA1 neurodegenerative pathway. Further, understanding the molecular mechanisms underlying the glial-neuronal crosstalk will help develop novel therapeutics against the non-autonomous polyglutamine pathology in multiple polyglutamine diseases.
